等待開盤 04-02 09:30:00 美东时间
+0.480
+2.00%
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59
今日重点评级关注:LUCID CAPITAL MARKETS:上调INmune Bio评级至"买入" 目标价从2美元升至9美元;Clear Street:维持MoonLake Immunotherapeutics Class A"买入"评级,目标价从45美元升至70美元
03-12 12:34
今日重点评级关注:Oppenheimer:维持Corbus制药控股"跑赢大市"评级,目标价从53美元升至57美元;Canaccord Genuity:维持WAVE Life Sciences"买入"评级,目标价从43美元升至52美元
03-11 12:40
The Q4 earnings report for Natures Sunshine Products (NASDAQ:NATR) was released...
03-11 05:30
Natures Sunshine Products (NASDAQ:NATR) sees FY2026 sales of $500.000 million-$515.000 million vs $494.394 million analyst estimate.
03-11 04:07
Natures Sunshine Products (NASDAQ:NATR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.19 by 57.89 percent. The company reported quarterly sales of $123.807 million which
03-11 04:07
Canaccord Genuity analyst Susan Anderson maintains Natures Sunshine Products (NASDAQ:NATR) with a Buy and raises the price target from $22 to $29.
03-11 00:12
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
Natures Sunshine Products (NASDAQ:NATR) is preparing to release its quarterly e...
03-09 23:02
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Equity-Insider.com News Commentary VANCOUVER, BC, Feb. 6, 2026 /PRNewswire/ -- Legacy strategies are stalling as consumers abandon static products...
02-06 22:07